Clinical Utility of myPath® Melanoma
Clinical Utility Studies
The clinical utility of the myPath® Melanoma score has been evaluated in two separate studies to best represent multiple aspects of the diagnostic and treatment paradigms.
These studies with experienced dermatopathologists demonstrate that use of the test increases the number of definitive diagnoses, decreases classification of lesions as ‘indeterminate’, and produces substantial changes in patient treatment.
Clinical Utility Study 1:
Prospective cohort (n=218) of cases submitted for testing in the clinical setting
56.6% increase in definitive diagnoses in ambiguous cases8
Clinical Utility Study 2:
Prospective cohort (n=77) of ambiguous cases (“indeterminate” per dermatopathologist)
Compared referring dermatopathologist pre-test management recommendation with actual patient treatment received by patient post-test at 6-12 months follow-up
71.4% change from pre-test treatment recommendation to actual treatment performed28